Hikma down, despite posting strong 2018 financials

13 March 2019

London-listed drugmaker Hikma Pharmaceuticals (LSE: HIK) today reported its preliminary audited results for the year ended December 31, 2018.

Group core revenue was $2,076 million, up 7%, withHikma’s injectables business accounting for about 40% of the total.Group core operating profit was $460 million, up 19%, and core basic earnings per share stood at 137.8 cents, up 31%

However, Hikma’s shares fell more than 5% to 1,572.39 pence by near midday, as the figures came in slightly below what the City had been expecting.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK